FRES - Kewajiban jangka dawa marang modal fresh2.co

Logo korporat perusahaan Fresh2 Group (FRES)

The price chart for Fresh2 Group Limited (FRES) reflects the dynamics of a company operating amidst fierce competition with Asian tech giants and low brokerage margins. The business relies on the PRC agro-IT segment, where financial stability is constrained by regulatory pressure and volatile demand, with the indicator standing at 0.00. Efforts to expand its B2B platform for the food industry are being hindered by rising marketing and delivery costs.

Fresh2 (FRES): Utang jangka dawa marang modal saka 21.02.2024 nganti 04.01.2025
Barang utama Fresh2 Group Ltd

For Fresh2 Group Limited (FRES), which develops digital B2B logistics in the US and China, the ratio of long-term debt to equity reflects a strategy of long-term infrastructure financing. This metric compares the volume of long-term liabilities against net shareholder assets. An increase in this indicator signals a growing credit load to scale the business, while a decrease in the coefficient confirms financial stability. It is critical for investors to assess the balance between low-cost debt capital and solvency risks.

Karo sapa Fresh2 Group Limited saingan

Rasio utang jangka dawa marang ekuitas Agilent Technologies, Inc.|Quest - Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal Illumina Platform (ILMN)|EXAS - Utang jangka dawa marang modal|Rasio utang jangka dawa marang modal revvity.com RVTY|Bio-Rad - Utang jangka dawa marang modal|NNNN: Utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Sterigenics|QuidelOrtho Inc. (QDEL) - Rasio utang jangka dawa marang modal|OPK (OPKO Health, Inc.) - Utang jangka dawa marang modal|Utang jangka dawa marang modal CDNA|Utang jangka dawa marang ekuitas Maravai LifeSciences Holdings, Inc. (MRVI)|Utang jangka dawa marang ekuitas Fulgent Genetics Inc FLGT|LAB: Rasio utang jangka dawa marang ekuitas|Cytek Corp - Kewajiban jangka dawa marang modal|Utang jangka dawa marang ekuitas OSUR (OraSure Technologies)|XGN - Rasio tanggungan utang jangka dawa marang modal|MDxHealth - Utang jangka dawa marang modal|LUCD (Lucid Diagnostics, Inc.) - Rasio tanggungan utang jangka dawa marang modal|PRE: Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka dawa marang modal Insight Molecular|TRIB - Utang jangka dawa marang modal|Kewajiban jangka dawa marang ekuitas PRPH (prophaselabs.com)|Utang jangka dawa marang ekuitas Ainos|Koefisien utang jangka dawa marang modal Co-Diagnostics Inc CODX|HSCS (Heart Test Laboratories Inc.) - Utang jangka dawa marang modal|BMRA: Kewajiban jangka dawa marang modal|cardiodiagnosticsinc.com - Utang jangka dawa marang ekuitas|viraxbiolabs.com (VRAX) - Rasio tanggungan utang jangka dawa marang modal|BJDX - Utang jangka dawa marang modal|Koefisien utang jangka dawa marang modal AWH|Utang jangka dawa marang ekuitas AXDX (Accelerate Diagnostics, Inc)|CNTG (Centogene) - Rasio utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal ENZ (Enzo Biochem)|Utang jangka dawa marang modal Genetic Technologies Ltd|ME - Tanggungan utang jangka dawa marang ekuitas|Utang jangka dawa marang ekuitas PMD (Psychemedics Corp.)